EXETER, N.H.--(BUSINESS WIRE)--Oct. 31, 2005--Bentley Pharmaceuticals, Inc. (NYSE: BNT), a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe, today announced that Fred Feldman, Ph.D., joins the Exeter-based research unit on October 31, 2005. Dr. Feldman is an experienced life sciences researcher with more than 25 years of product development expertise. Dr. Feldman received his B.S. degree in Biochemistry from the University of Chicago and Ph.D. in Biochemistry from Purdue University. While Vice President of Pre-Clinical R&D at Armour Pharmaceutical Company and later at Rhone Poulenc Rorer after its acquisition of Armour, he developed new products and spearheaded registration activities in the U.S. and international markets. He was a leader in the development of lifesaving drugs for chronic diseases and replacement therapies that were registered and commercialized worldwide. Dr. Feldman went on to become Senior Vice President, Worldwide Head of Pre-Clinical R&D and Head of Biotechnology for Centeon, LLC and Aventis Behring, both Aventis Pharma subsidiaries, setting strategic scientific direction in such disciplines as gene therapy and therapeutic protein delivery. He has also been a high-level advisor to various venture capital investment organizations involved in a broad range of biotechnology and pharmaceutical applications.
